This forest plot shows the effect of amyloid reduction on cognitive decline in each trial. If a drug worked via amyloid mechanisms, we’d expect increases in the change in MMSE, or positive effects in the forest plot. Estimates are either small or are very imprecise.

What i’d really like is a treatment that works to end AD- not just #MoreTime treating loved ones with ineffective drugs with bad side effects. Should FDA approve drugs because we wish they would work or because we know they work?

Excited to join #SER2021 to present work w/ Justin White William Dow on IV methods to study peer effects in health behaviors. Tune in for great content on identification, inference & more from Elizabeth Diemer, Eric Tchetgen Tchetgen Willa D Brenowitz & discussant Maria Glymour!

The FDA's reasoning and procedures over the scientifically inexplicable approval of aducanumab just get murkier with reading of these further documents. Most telling has to be that their internal statisticians have consistently opposed approval at all stages.

Interested in instrumental variable approaches including Mendelian randomization? Come check out our session! #SER2021 Fri June 25 10:15-11:45am MT Featuring talks by Chris Lowenstein, Elizabeth Diemer, Eric Tchetgen Tchetgen, and discussion by Maria Glymour #EpiTwitter

I don't understand the reasoning that approving a potentially ineffective drug is a big success, or that providing billions in profit for a potentially ineffective or even harmful drug will stimulate the type of innovation we're hoping for. Seems circular. #aducanumab

I'm thrilled to share that we are recruiting for SleepTIGHT ! DM 👉if you are suffering from sleep problems &memory loss & like to try a FDA-approved digital sleep therapeutic for FREE! #insomnia #clinicaltrial UCSF Psychiatry and Behavioral Sciences UCSF Epidemiology & Biostatistics UCSF Geriatrics Global Brain Health Institute

Instead of grousing you’ve got til Aug 11 to comment on aducanumab Aduhelm to CMS. You can do it now. National Coverage Analysis (NCA) Tracking Sheet for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease (CAG-00460N) cms.gov/medicare-cover…

Why do amyloid lowering Rx accelerate brain atrophy? #Donanemab "accelerated brain volume loss in the TRAILBLAZER-ALZ trial. This cannot be attributed to reduction in plaque volume" Surely this can't be a desirable effect of "effective" Rx? tinyurl.com/ykt6dj3t Robert Howard

Please take the time to comment. The CMS decision was brave - a step towards finding answers that will help people living the reality of AD instead of the magical thinking that if we hope hard enough, it must be true. #aduhelm #FindOutIfItWorks.

To my disability community and allies - NIH is asking for public feedback on two Requests for Information (RFI) that impact the disability community. Please consider responding. Links are below. (1/7)

New online! Ventricular enlargement caused by aducanumab dlvr.it/SNrrTX

Excited our Perspective on the importance of observational studies in AD and dementia research is out! With Kristine Yaffe UCSF Center for Population Brain Health (K. Yaffe) UC San Francisco #alzheimerdisease #epitwitter

Very concerning about the new drug w/modest effects for Alzheimer's disease (AD) "If the patient hadn’t been on lecanemab she would be alive today.” Underlying cerebral amyloid angiopathy is present in nearly half of AD patients science.org/content/articl… Charles Piller Science Magazine

Paper Call for Special Issue on Sensory Changes and Alzheimer’s Disease and Related Dementias! Deadline Aug 15th alz-journals.onlinelibrary.wiley.com/journal/235287…

Deadline is now extended to Sep 15th!

Check out our paper on AD genetic risk and MRI volumes across age. Great work led by by Peter Buto! We found higher AD genetic risk was associated with reduced volumes as early as age 50 for several regions, incl hippocampus. AD begins in midlife? doi.org/10.1002/alz.13…

Our study on vision impairment, eye conditions, and dementia was published by JAMA Network Open! Excellent work by Erin Ferguson using Mendelian randomization and neuroimaging in UK Biobank. Findings support cataracts as a risk factor for dementia, especially vascular dementia.